News

The first non-living vaccine against toxoplasmosis: a world premiere by Vaxinano. (Ducournau C. & al. Front. Immunol. 2020)

Wednesday, September 09th 2020

In this publication, Vaxinano’s nasal vaccine administered using a nasal spray protects sheep against chronic and congenital Toxoplasma gondii infection (Ducournau C. & al. Front. Immunol. 2020). This vaccine will also benefit the general public health by reducing the socio-economic burden associated to the consumption of contaminated meat, the major source of human toxoplasmosis.

Crossing the mucus barrier with a nasal vaccine: a strong breakthrough by Vaxinano. (Fasquelle F. & al. ACS Appl. Bio Mater. 2020 )

Monday, August 03rd 2020

Mucus is a natural barrier that impedes pathogens to invade the body and initiate infection. Contrary to most nanocarriers, Vaxinano’s starch nanoparticles are able to cross the mucus layer and induce an immune protective response (Fasquelle F. & al., ACS Appl. Bio Mater. 2020). This explains why Vaxinano’s vaccines are efficient via the mucosal administration route, acting against a large number of pathogens - such as Influenza viruses and Toxoplasma gondii - without the addition of any adjuvants (Le MQ. & al., Int. J. Pharm. 2020; Ducournau C. & al., Front. Immunol. 2020).

Vaxinano’s technology in use against the coronavirus pandemic.

Tuesday, June 30th 2020

The French research national agency (ANR) has granted Vaxinano funding to develop an innovative vaccine against Covid-19.

Vaxinano recruits an animal vaccine project leader

Wednesday, April 29th 2020

The Vaxinano's technology, high hope for Covid-19 vaccine (Le MQ. & al., Int. J. Pharm. 2020)

Thursday, April 16th 2020

Nasal vaccination with Vaxinano's nanoparticles against flu virus inhibits virus transmission

Didier Betbeder, CEO & CSO of Vaxinano, interviewed in Parole d'Experts de La Tribune (french)

Wednesday, February 12th 2020

Didier Betbeder, CEO & CSO of Vaxinano, explains how innovative and efficient is its vaccine platform.

Vaxinano presents its vaccine platform technology at the french society of immunology

Thursday, January 16th 2020

Didier Betbeder, CEO & CSO of Vaxinano, presents the vaccine platform to Vaccinology Club of the French Society for Immunology

Vaxinano presents preclinical results of its anti-toxoplasma vaccine

Thursday, December 05th 2019

Didier Betbeder, CEO & CSO of Vaxinano, presents for the first time the preclinical results of the anti-toxoplasma vaccine, including non-human primates.

New Contract

Monday, July 01st 2019

Vaxinano Announces the Signing of a Third Research and Development Program with a Leader in the Vaccine Industry.

An E.coli vaccine as an alternative to the overuse of antibiotics in poultry

Thursday, June 06th 2019

Faced with the worldwide emergence of antibiotic resistance, Vaxinano obtains funding for research with Immunova Analises Biologicas and Lesaffre International to develop a vaccine against avian colibacillosis.